@incollection{,
	
					
					
					782B288E931F5BE2C82FC1EC1C0448EA
				,
	author={{Andy} and {Robertus BebetPrasetyo} and {Universitas Indonesia}},
	journal={{Global Journal of Medical Research}},
	journal={{GJMR}}2249-46180975-588810.34257/GJMR,
	address={Cambridge, United States},
	publisher={Global Journals Organisation}1961720
}

@incollection{b0,
	
	
		,
	title={{Prostate cancer epidemiology in the United States}}
		,
	author={{
			OBrawley
		}}
	
	
		,
	journal={{World J Urol}}
		
			30
			2
			
			,
	year={2012 Apr 1}
		
	

}

@book{b1,
	
	
		,
	title={{Cancer incidence in five continents}}
		,
	author={{
			D MParkin
		} and {
			SWhelan
		} and {
			JFerlay
		} and {
			LRteppo
		} and {
			DThomas
		}}
		
		
		
		
		
			VIII
		
	

}

@incollection{b2,
	
	
		,
	title={{}}
	
	
		,
	journal={{IARC Sci Publ}}
		
			155
			
			,
	year={2002}
		
	

}

@incollection{b3,
	
	
		,
	title={{Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths}}
		,
	author={{
			RSiegel
		} and {
			EWard
		} and {
			OBrawley
		} and {
			AJemal
		}}
		
		
		
	
	
		,
	journal={{CA Cancer J Clin}}
		
			61
			4
			
			,
	year={2011}
		
	

}

@incollection{b4,
	
	
		,
	title={{Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate}}
		,
	author={{
			CHuggins
		} and {
			CVHodges
		}}
		
	
	
		,
	journal={{Cancer Res}}
		
			1
			4
			
			,
	year={1941 Apr 1}
		
	

}

@incollection{b5,
	
	
		,
	title={{Comparison of efficacy and safety of 1-and 3-month luteinizing hormonereleasing hormone agonist depots as initial therapies for prostate cancer}}
		,
	author={{
			OIshizuka
		} and {
			ONishizawa
		} and {
			SNishizawa
		} and {
			TSatoh
		} and {
			MWajiki
		} and {
			HKiyokawa
		}}
		
		
		
		
		
	
	
		,
	journal={{Int J Clin Oncol}}
		
			18
			3
			
			,
	year={2013}
		
	

}

@incollection{b6,
	
	
		,
	title={{Profil penderita kanker prostat di RSOP Prof. Dr. R. D. Kandou Manado periode tahun 2013-2015}}
		,
	author={{
			V RSolang
		} and {
			AMonoarfa
		} and {
			FTjandra
		}}
		
		
	
	
		,
	journal={{ECL}}
		
			4
			2
			
			,
	year={2016}
		
	

}

@incollection{b7,
	
	
		,
	title={{Global treatment patterns for late-stage prostate cancer: Updated results from ASPIRE-PCa}}
		,
	author={{
			N WClarke
		} and {
			DeSantis
		} and {
			MCostello
		} and {
			A JChang
		} and {
			Y-HPickles
		} and {
			TPompeo
		} and {
			A C
		}}
		
		
		
		
		
		
	
	
		,
	journal={{Ann Oncol}}
		
			27
			6
			747
			,
	year={2016}
		
	

}

@incollection{b8,
	
	
		,
	title={{The Current State of Hormonal Therapy for Prostate Cancer}}
		,
	author={{
			B AHellerstedt
		} and {
			KJPienta
		}}
		
	
	
		,
	journal={{CA Cancer J Clin}}
		
			52
			3
			
			,
	year={2009}
		
	

}

@incollection{b9,
	
	
		,
	title={{LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action}}
		,
	author={{
			PLimonta
		} and {
			M MMarelli
		} and {
			RMoretti
		}}
		
		
	
	
		,
	journal={{Expert Opin Investig Drugs}}
		
			10
			4
			
			,
	year={2001 Apr}
		
	

}

@incollection{b10,
	
	
		,
	title={{Gonadotropin-releasing hormone: An update review of the antagonists versus agonists}}
		,
	author={{
			HVan Poppel
		} and {
			LKlotz
		}}
		
	
	
		,
	journal={{Int J Urol}}
		
			19
			7
			
			,
	year={2012 Jul 1}
		
	

}

@book{b11,
	
	
		,
	title={{Pretreatment prostatespecific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy}}
		,
	author={{
			M FO'brien
		} and {
			A MCronin
		} and {
			P AFearn
		} and {
			BSmith
		} and {
			JStasi
		} and {
			BGuillonneau
		}}
		
		
		
		
		
		
	

}

@incollection{b12,
	
	
		,
	title={{}}
	
	
		,
	journal={{J Clin Oncol Off J Am Soc Clin Oncol}}
		
			27
			22
			
			,
	year={2009 Aug 1}
		
	

}

@incollection{b13,
	
	
		,
	title={{Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy}}
		,
	author={{
			DPalma
		} and {
			STyldesley
		} and {
			PBlood
		} and {
			MLiu
		} and {
			JMorris
		} and {
			TPickles
		}}
		
		
		
		
		
	
	
		,
	journal={{Int J Radiat Oncol Biol Phys}}
		
			67
			5
			
			,
	year={2007 Apr 1}
		
	

}

@incollection{b14,
	
	
		,
	title={{Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy}}
		,
	author={{
			T KChoueiri
		} and {
			WXie
		} and {
			D'amico
		} and {
			R WRoss
		} and {
			J CHu
		} and {
			MPomerantz
		}}
		
		
		
		
		
	
	
		,
	journal={{Cancer}}
		
			115
			
			,
	year={2009}
		
	

}

@book{b15,
	
	
		,
	title={{Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer}}
		,
	author={{
			F LCury
		} and {
			DHunt
		} and {
			MRoach
		} and {
			WShipley
		} and {
			EGore
		} and {
			I-CHsu
		}}
		
		
		
		
		
		
			,
	year={2013 Jun 1}
			119
			
		
	

}

@incollection{b16,
	
	
		,
	title={{Goserelin versus leuprolide in the chemical castration of patients with prostate cancer}}
		,
	author={{
			É DSilva
		} and {
			UFerreira
		} and {
			WMatheus
		} and {
			E FFaria
		} and {
			GDSilva
		} and {
			MSaito
		}}
		
		
		
		
		
	
	
		,
	journal={{Int Urol Nephrol}}
		
			44
			4
			
			,
	year={2012 Aug 1}
		
	

}

@incollection{b17,
	
	
		,
	title={{Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer}}
		,
	author={{
			YFujii
		} and {
			JYonese
		} and {
			SKawakami
		} and {
			SYamamoto
		} and {
			YOkubo
		} and {
			IFukui
		}}
		
		
		
		
		
	
	
		,
	journal={{BJU Int}}
		
			101
			9
			
			,
	year={2008 May 1}
		
	

}